跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
Approvals
/
Health Canada
/
GAVRETO
Authorized
STANDARD
GAVRETO
Hoffmann-La Roche Limited
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
3dfcfc66413122a5
Company
Hoffmann-La Roche Limited
Type
Standard
Approval Details
Approval Id
3dfcfc66413122a5
Drug Approval Canada Name
GAVRETO
Product Name
GAVRETO
Status
Cancelled Post Market
Status Date
2025-02-26
Original Market Date
2021-11-12
Din
02517590
Drug Class
Human
Dosage Form
Capsule
Route Of Administration
Oral
Schedule
Prescription
Ahfs
10:00.00
Atc Original
L01EX23 PRALSETINIB
Atc Name
l 01 ex 23
Aig Number
0163030001
Company Name
Hoffmann-La Roche Limited
Company Address
7070 Mississauga Road, Mississauga, Ontario, Canada, L5N 5M8
Active Ingredients
PRALSETINIB
100 MG
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
3dfcfc66413122a5
Type
Standard
Back to Health Canada Approvals
GAVRETO - Health Canada Drug Approval Details